EP4444361A4 - IN VIVO ADMINISTRATION TO IMMUNE CELLS - Google Patents

IN VIVO ADMINISTRATION TO IMMUNE CELLS

Info

Publication number
EP4444361A4
EP4444361A4 EP22905102.4A EP22905102A EP4444361A4 EP 4444361 A4 EP4444361 A4 EP 4444361A4 EP 22905102 A EP22905102 A EP 22905102A EP 4444361 A4 EP4444361 A4 EP 4444361A4
Authority
EP
European Patent Office
Prior art keywords
immune cells
vivo administration
vivo
administration
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22905102.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4444361A2 (en
Inventor
Michael Klichinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carisma Therapeutics Inc
Original Assignee
Carisma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carisma Therapeutics Inc filed Critical Carisma Therapeutics Inc
Publication of EP4444361A2 publication Critical patent/EP4444361A2/en
Publication of EP4444361A4 publication Critical patent/EP4444361A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP22905102.4A 2021-12-09 2022-12-08 IN VIVO ADMINISTRATION TO IMMUNE CELLS Pending EP4444361A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163287725P 2021-12-09 2021-12-09
PCT/US2022/052207 WO2023107593A2 (en) 2021-12-09 2022-12-08 In vivo delivery to immune cells

Publications (2)

Publication Number Publication Date
EP4444361A2 EP4444361A2 (en) 2024-10-16
EP4444361A4 true EP4444361A4 (en) 2025-12-10

Family

ID=86731192

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22905102.4A Pending EP4444361A4 (en) 2021-12-09 2022-12-08 IN VIVO ADMINISTRATION TO IMMUNE CELLS

Country Status (4)

Country Link
EP (1) EP4444361A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546641A (cg-RX-API-DMAC7.html)
AU (1) AU2022407035A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023107593A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途
WO2024026284A2 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
CN117343908B (zh) * 2023-12-05 2024-02-09 南京大学 一种通过真菌精准激活的car-t细胞、制备方法、应用及药物组合物
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN120695211A (zh) * 2025-06-25 2025-09-26 广东医科大学附属医院 mRNA组合物及其在制备肝纤维化治疗药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296676A1 (en) * 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2020194306A1 (en) * 2019-03-26 2020-10-01 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
EP4118098A4 (en) * 2020-03-11 2024-06-12 The Trustees of The University of Pennsylvania METHOD AND COMPOSITION FOR GENE DELIVERY USING AN MANIPULATED VIRUS PARTICLE
US20240245805A1 (en) * 2020-03-20 2024-07-25 Orna Therapeutics, Inc. Circular rna compositions and methods
MX2022015888A (es) * 2020-06-26 2023-03-28 Carisma Therapeutics Inc Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296676A1 (en) * 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2020194306A1 (en) * 2019-03-26 2020-10-01 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing cars

Also Published As

Publication number Publication date
JP2024546641A (ja) 2024-12-26
WO2023107593A3 (en) 2023-07-27
WO2023107593A2 (en) 2023-06-15
AU2022407035A1 (en) 2024-05-23
EP4444361A2 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
FR26C1011I1 (fr) Composés thérapeutiquement actifs et leurs méthodes d'utilisation
IL286897A (en) Providing medical devices with sensing functionality
IL291394A (en) Dosing combinations for reducing undesired humoral immune responses
CL2018000457A1 (es) Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina
EP2844269A4 (en) TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES
IL253879A0 (en) Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
EP3557634A4 (en) LAMINATED SOLAR CELL WITH INTER-SLICE CONNECTING STRUCTURE AND LAMINATED SOLAR CELL
EP2822614A4 (en) MODULAR IMPLANTABLE MEDICAL PUMP
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
EP2971011A4 (en) FREIGHT DELIVERY IN LIVING CELLS BY MEANS OF PHOTOTHERMAL PLATFORMS
EP2970897A4 (en) IN VITRO PREPARATION OF PRECURSOR CELLS FOR MEDIUM GANGLIONIC EMINENCE
EP2970880A4 (en) MULTIFUNCTIONAL UNLIMITED TOOTHMARK STEM CELLS AND THERAPEUTIC APPLICATIONS
EP2560624A4 (en) THERAPEUTIC FORMULATION FOR REDUCED MEDICAMENT SIDE EFFECTS
EP3075218A4 (en) INTEGRATION OF A MICRO-INVERTER IN A PHOTOVOLTAIC MODULE
EP2817275A4 (en) CONVERSION OF LIPIDES
EP2866878A4 (en) ACTIVE ELECTRIC HEART DISTRIBUTION
EP2971635A4 (en) PRE-CHAIR WITH ACTIVE FLUSHING
IL243627A0 (en) High potency pancreatin pharmaceutical compositions
EA201591567A1 (ru) Новые производные пиридина
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EP4167937A4 (en) PROBIOTIC SKIN FORMULATIONS
IL304559A (en) Self-polarizing immune cells
EP3549590A4 (en) CELL PREPARATION
EP3344760A4 (en) GENERALLY MANUFACTURED DRUG-RESISTANT T CELLS AND METHOD OF USE THEREOF
CU24139B1 (es) Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240709

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101AFI20251104BHEP

Ipc: A61K 35/17 20150101ALI20251104BHEP

Ipc: C12N 5/10 20060101ALI20251104BHEP

Ipc: C12N 15/85 20060101ALI20251104BHEP

Ipc: A61K 38/17 20060101ALI20251104BHEP

Ipc: C12N 5/0786 20100101ALI20251104BHEP

Ipc: A61K 40/17 20250101ALI20251104BHEP

Ipc: A61K 40/19 20250101ALI20251104BHEP

Ipc: A61K 40/31 20250101ALI20251104BHEP

Ipc: A61K 40/35 20250101ALI20251104BHEP

Ipc: C07K 14/54 20060101ALI20251104BHEP

Ipc: C07K 14/565 20060101ALI20251104BHEP

Ipc: C07K 14/715 20060101ALI20251104BHEP